Objectives: Today, metformin is considered to be the first-choice drug and is considered the gold standard for most people with type 2 diabetes. Metformin is the most commonly used diabetic medication used worldwide. Metformin use in patients with congestive heart failure, moderate chronic kidney disease, or chronic liver disease with hepatic impairment is associated with improvements in mortality. Research has shown that metformin also has a protective effect on endothelium by decreasing endothelial vascular reactivity. We hypothesize that metformin will decrease restenosis/reintervention rates in patients receiving lower extremity arterial stents.
Author Disclosures: A. Alsheekh: Nothing to disclose; E. Ascher: Nothing to disclose; M. A. Goldstein: Nothing to disclose; A. Hingorani: Nothing to disclose; T. Izakovich: Nothing to disclose; P. Kibrik: Nothing to disclose; C. M. Monteleone: Nothing to disclose; J. Victory: Nothing to disclose. Objectives: Functional popliteal artery entrapment syndrome (FPAES) results from hypertrophied gastrocnemius, soleus, and/or plantaris muscles, without identifiable anatomic abnormality. Historically, FPAES has been managed with surgical myotomy. We reviewed the literature to evaluate the results of surgery along with a newer treatment (botulinum toxin A injection) for this rare form of claudication.
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Functional Popliteal Artery Entrapment
Methods: A systematic literature search of PubMed, Cochrane, and Ovid yielded 1546 publications, Of these, 738 articles were eliminated based on abstract and title screening, 808 were assessed for eligibility, and 803 were excluded based on established exclusion criteria. Ultimately, data were extracted from five articles. From these we obtained the number of patients, demographic information, preoperative workup, surgical treatment details, follow-up imaging, and results of treatment.
Results: A total of 101 patients (61% female) were studied. Mean age was 27.5 years. Noninvasive testing revealed bilateral findings in 24%. Treatment involved surgical myotomy (93; four studies), and botulinum toxin injection (8; one study). Adjunctive vascular reconstruction was performed in eight of the surgical cases. FPAES patients who underwent surgical management were evaluated subjectively for symptomatic improvement of symptoms, and majority had duplex ultrasound studies in follow-up. Symptoms recurred in 8% (8 of 93), and 7.5% (7 of 93) had revision surgical procedures. Complications in the surgical management group included seroma/hematoma in 4% (4 of 93) and infection in 2% (2 of 93). Mean follow-up time for patients was 22 months. For the botulinum toxin treatment group, improvement of symptoms was achieved in 81% of patients (13 of 16 limbs). Patients treated with botulinum toxin did not have imaging in follow-up. No complications were reported. The average follow-up time was 53 days for the botulinum group.
Conclusions: This review suggests FAPES may be treated successfully with surgical myotomy plus adjunctive vascular reconstruction if necessary (Fig) . Botulinum toxin A injection may improve symptoms shortterm, potentially delaying or eliminating the need for surgery in select patients. It may also have value as a diagnostic procedure.
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IP221. Early and Follow-Up Results of Endovascular Treatment of Chronic Obstructive Disease of the External Iliac Artery
Aaron Fargion, Walter Dorigo, Fabrizio Masciello, Sara Speziali, Benedetta Giannasio, Valentina Sanna, Elena Giacomelli, Carlo Pratesi. University of Florence, Florence, Italy
Objectives: This study retrospectively evaluated perioperative and long-term results of endovascular management of isolated chronic obstructive disease of the external iliac artery (EIA) in a single-center experience.
Methods: From January 2010 to December 2015, 162 endovascular interventions for aortoiliac obstructive disease were performed. Data concerning these interventions were prospectively collected into a dedicated database. A post hoc analysis of the datae was performed, and 47 patients treated for chronic obstructive disease of the EIA were found. Perioperative (<30 days) and follow-up results were analyzed. The analysis of follow-up results was stopped at March 2016. Late outcomes were assessed in with life-table analysis and Kaplan-Meier curves. Univariate and multivariate (forward stepwise Cox regression) analyses for longterm primary patency were performed.
Results: The indication for treatment was the presence of severe lifestyle-limiting intermittent claudication after the failure of other conservative measures in 40 patients, and seven patients had critical limb ischemia (CLI; rest pain in 5 and ulcers in 2). Occlusion of the EIA was present in 23 patients, and 24 patients had a stenotic EIA (in 2 cases bilateral). The mean length of the lesion was 6.1 6 2.4 cm for stenoses and 8.1 6 2.3 cm for occlusions (P ¼ .4). Hybrid intervention with femoral endarterectomy and patching was performed in 13 patients. All but one patients had one or more stents inserted, the mean number of placed stents was 1 (range 0-2) with a mean length of 94 6 28 mm. No perioperative deaths, thromboses, or local complication occurred. Follow-up was performed in 46 patients (98%) with a mean duration of 27.3 6 20 months; the mean follow-up index was 0.86 6 0.18. Estimated 4-year survival was 92% (standard error [SE], 0.05); at the same time interval primary patency, assisted primary patency and secondary patency rates were 81% (SE, 0.07), 91.8% (SE, 0.05) and 94.5% (SE, 0.04). The cumulative reintervention rate at 4 years was 16.9% (SE, 0.08). The presence of CLI (P ¼ .08, log-rank 2.9), the use of a hybrid intervention (P ¼ .07, log-rank 3.1), and a coverage of the artery of >8 cm (P ¼ .2, log-rank 1.3) entered the multivariable analysis, but none of them was independently associated with poorer primary patency rates.
Conclusions: Endovascular surgery to treat occlusive lesions of the EIA provided good short-and midterm patency and low early morbidity and mortality. There was a trend toward poorer patency rates in patients with CLI and in those with complex lesions, requiring further investigations.
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Objectives: Patients with critical limb ischemia (CLI) may face numerous barriers to care, including distance and burden of coordinating travel required for multiple inpatient and outpatient visits. We aimed to investigate perceptions and attitudes of patients with CLI to the possibility of providing vascular care through telemedicine.
Methods: Patients being treated for Rutherford class 5 CLI underwent semistructured interviews with questions focused on current ulcer issues, comfort with current health providers, ability and willingness to see specialists outside of their region, and comfort with health care provided through technology. A mixed-methods approach was used to compare responses and develop themes for a larger patient survey.
Results: Eleven patients with a mean age of 60 years (range, 35-79 years) were interviewed. Diabetes mellitus was present in eight patients (73%). Ten of the patients could describe their wound and current treatment regimen. Patients with ulcers due to peripheral artery disease (PAD) were unfamiliar with the terminology but did recall being told they had "bad blood flow." Patients expressed a mean confidence score of 3.36 of 4 in their current provider. Factors that decreased a patient's confidence included the providers' "ability to hear" the patient's concerns. Seven patients required transport by others, and four drove themselves. All patients were willing to make three or more visits a month to their provider for treatment. Nine patients had Internet at home, and six of these felt comfortable using technology on their own. Eight patients expressed a "lack of trust" regarding seeing an unknown provider over the Internet. Four of these believed an endorsement from their primary care provider could change this perception, but remained "unsure they could form a relationship" with the provider through the Internet. Themes of uncertainty for seeing a provider through the internet centered around "security of personal information," "ability to maintain confidentiality" of the visit, and limited ability to "get to know" the provider.
Conclusions: In this exploratory study of CLI patients, 81% have home Internet and >50% felt comfortable using technology on their own. Primary care provider recommendation can improve patient willingness to use technology for initial specialist consultation, but focused attention must be placed on development of the patientprovider relationship through telemedicine. Using themes developed from this qualitative study, we plan to develop a survey applicable to all patients with CLI to understand their concerns and technological capabilities.
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VascTrac: A Study of Peripheral Artery Disease via Smartphones to Improve Remote Disease Monitoring and Postoperative Surveillance Raheel Ata, Neil Gandhi, Hannah Rasmussen, Osama El-Gabalawy, Anika Agrawal, Sunaina Kongara, Muhammad Majeed, Oliver Aalami. Stanford University, Stanford, Calif Objectives: VascTrac is the first smartphone-based prospective longitudinal study that aims to enable researchers to track the progression of peripheral artery disease (PAD) and monitor patient-reported outcomes of exercise therapies, surgical procedures, and medications. By remotely monitoring daily activity of patients with smartphones, VascTrac aims to introduce precision medicine into the surveillance and management of PAD.
Methods: We are running a 2-year study completely through the VascTrac iOS smartphone app (www.vasctrac.stanford.edu) that we
